Clinical trial
Study of ALXN1210 in Complement Inhibitor Treatment-Naïve Adult and Adolescent…
NCT02949128 · Alexion Pharmaceuticals, Inc., Industry · Completed
Key facts
| NCT number | NCT02949128 |
|---|---|
| Title | Study of ALXN1210 in Complement Inhibitor Treatment-Naïve Adult and Adolescent Participants With Atypical Hemolytic Uremic Syndrome (aHUS) |
| Official title | Single Arm Study of ALXN1210 in Complement Inhibitor Treatment-naïve Adult and Adolescent Patients With Atypical Hemolytic Uremic Syndrome (aHUS) |
| Lead sponsor | Alexion Pharmaceuticals, Inc., Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Atypical Hemolytic Uremic Syndrome (aHUS) |
| Intervention type | Biological |
| Interventions | Ravulizumab |
| Enrollment | 58 |
| Start date | Jan 11, 2017 |
| Primary completion | Jan 24, 2023 |
| Completion | Jan 24, 2023 |
| First posted | Oct 31, 2016 |
| Last update posted | Feb 20, 2024 |
| Countries | Australia, Austria, Belgium, Canada, France, Germany, Italy, Japan, Russia, South Korea, Spain, Taiwan and 2 more |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: